Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
Smith RA, Raugi DN, Kiviat NB, Hawes SE, Mullins JI, Sow PS, Gottlieb GS; University of Washington-Dakar HIV-2 Study Group.
AIDS. 2011 Nov 28;25(18):2235-41.
Related citations
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y, Marks S.
AIDS. 2011 Nov 28;25(18):2249-58.
Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
Soriano V, Sherman KE, Rockstroh J, Dieterich D, Back D, Sulkowski M, Peters M.
AIDS. 2011 Nov 28;25(18):2197-208. Review.
Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps.
Schaible B, Taylor CT, Schaffer K.
Antimicrob Agents Chemother. 2012 Apr;56(4):2114-8. Epub 2012 Jan 30.
Carbapenem resistance in Elizabethkingia meningoseptica is mediated by metallo-β-lactamase BlaB.
González LJ, Vila AJ.
Antimicrob Agents Chemother. 2012 Apr;56(4):1686-92. Epub 2012 Jan 30.
Mutations in the β subunit of RNA polymerase alter intrinsic cephalosporin resistance in Enterococci.
Kristich CJ, Little JL.
Antimicrob Agents Chemother. 2012 Apr;56(4):2022-7. Epub 2012 Jan 30.
Small-angle X-ray scattering analysis of the bifunctional antibiotic resistance enzyme aminoglycoside (6') acetyltransferase-ie/aminoglycoside (2'') phosphotransferase-ia reveals a rigid solution structure.
Caldwell SJ, Berghuis AM.
Antimicrob Agents Chemother. 2012 Apr;56(4):1899-906. Epub 2012 Jan 30.
MurAA is required for intrinsic cephalosporin resistance of Enterococcus faecalis.
Vesić D, Kristich CJ.
Antimicrob Agents Chemother. 2012 May;56(5):2443-51. Epub 2012 Jan 30.
Evolutionary changes in antimicrobial resistance of invasive Neisseria meningitidis isolates in Belgium from 2000 to 2010: increasing prevalence of penicillin nonsusceptibility.
Bertrand S, Carion F, Wintjens R, Mathys V, Vanhoof R.
Antimicrob Agents Chemother. 2012 May;56(5):2268-72. Epub 2012 Jan 30.
Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States.
Park YS, Adams-Haduch JM, Shutt KA, Yarabinec DM 3rd, Johnson LE, Hingwe A, Lewis JS 2nd, Jorgensen JH, Doi Y.
Antimicrob Agents Chemother. 2012 Apr;56(4):1870-6. Epub 2012 Jan 30.
Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.
Fox ZV, Cozzi-Lepri A, D'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD; EuroSIDA.
Antivir Ther. 2011;16(5):781-5.
Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.
Hamelin ME, Baz M, Bouhy X, Beaulieu E, Dubé K, Mallett C, Boivin G.
Antivir Ther. 2011;16(5):775-9.
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Gathe J, Andrade-Villanueva J, Santiago S, Horban A, Nelson M, Cahn P, Bogner J, Spencer D, Podzamczer D, Yong CL, Nguyen T, Zhang W, Drulak M, Quinson AM.
Antivir Ther. 2011;16(5):759-69.
Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
McKinnon JE, Delgado R, Pulido F, Shao W, Arribas JR, Mellors JW.
Antivir Ther. 2011;16(5):725-32.
Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates.
Sheaffer AK, Lee MS, Hernandez D, Chaniewski S, Yu F, Falk P, Friborg J, Zhai G, McPhee F.
Antivir Ther. 2011;16(5):705-18.
HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Du Jeong I, Bang SJ, Park NH.
Antivir Ther. 2012;17(2):387-94. doi: 10.3851/IMP1945. Epub 2011 Nov 2.
Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, Mpoudi-Ngolé E, Ducos J, Delaporte E, Laurent C.
Antivir Ther. 2012;17(2):321-6. doi: 10.3851/IMP1911. Epub 2011 Sep 23.
Research into new antibiotics is not the answer to resistance.
Hall MH.
BMJ. 2011 Dec 13;343:d8050. doi: 10.1136/bmj.d8050. No abstract available.
Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.
Shen GH, Tsao TC, Kao SJ, Lee JJ, Chen YH, Hsieh WC, Hsu GJ, Hsu YT, Huang CT, Lau YJ, Tsao SM, Hsueh PR.
Int J Antimicrob Agents. 2012 Mar;39(3):201-5. Epub 2012 Jan 28.
A carbapenem-resistant Klebsiella pneumoniae epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac(6')-Ib.
Warburg G, Hidalgo-Grass C, Partridge SR, Tolmasky ME, Temper V, Moses AE, Block C, Strahilevitz J.
J Antimicrob Chemother. 2012 Apr;67(4):898-901. Epub 2012 Jan 26.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on